Recent Updates
Recently added Catalysts

Adverum Biotechnologies, Inc.

ADVMFDA catalysts, PDUFA dates & pipeline intelligence
$4.36
▲ +0.12 · +2.83%

Last traded Dec 8, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ADVM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.7852W HIGH $6.07
Volume
1.02 M
Value Traded
4.43 M
Short % Float
2.5%
Days to Cover
1.0
+6.08%Week
+2.11%1 Month
+24.22%3 Month
+54.61%6 Month
-96.81%5 Year
-98.26%All Time

Cash Data

Unlock ADVM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
96.26 M
EPS (TTM)
-8.57
P/E Ratio
-
Ent. Value
159.14 M
Total Shares
20.98 M
Float Shares
17.46 M
Insiders
33.78%
Institutions
58.54%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
Ixo-vec (ixoberogene soroparvovec)
nAMD (neovascular age-related macular degeneration)
Fast TrackRMAT
Phase 3Gene TherapiesOphthalmologic System
Unlock every ADVM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ADVM Catalyst Timeline

Dated clinical, regulatory and corporate events for Adverum Biotechnologies, Inc.

Unlock the full ADVM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ADVM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-03-31Ixo-vec Phase 2 data presentation Phase 2
Unlock 2 more ADVM historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 5 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
ADVM-022 Gene therapyNCT05536973Neovascular Age-related Macular DegenerationPhase 2 ACTIVE NOT_RECRUITING 69Aug 1, 2028
Ixo-vec Gene therapyNCT06856577Neovascular Age-Related Macular Degeneration (nAMD)Phase 3 ACTIVE NOT_RECRUITING 845Nov 23, 2030
Ixo-vec Gene therapyNCT07630649Neovascular Age-Related Macular Degeneration (nAMD) Wet AMDPhase 2 RECRUITING 15Jun 1, 2031
6E11 vg/eye of ADVM-022 Monoclonal antibodyCompletedNCT04418427Diabetic Macular EdemaPhase 2 COMPLETED 36Jun 14, 2023
ADVM-022 Monoclonal antibodyCompletedNCT03748784Wet Age-related Macular DegenerationPhase 1 COMPLETED 30Jun 22, 2022
Unlock the ADVM pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ADVM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
ixoberogene soroparvovec
Fast TrackRMAT
wet age-related macular degenerationPhase 22024-11-1552-week LUNA phase 2 clinical data and 4-year OPTIC clinical dataRead MoreAdverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design ElementsRead More
Scroll for more · summaries link to the source press release
Unlock every ADVM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ADVM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Fischer LaurentDirector, Officer (CEO, PRESIDENT AND DIRECTOR)Option 150,000 351,513 held$4.20 12/09/2025
Unlock the full ADVM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in ADVM

Fund % of Portfolio Current MV Shares Owned Activity
Frazier Life Sciences Management, L.P. 0.3 % (200 %) 9.41 M 2.08 M 94.29% ( 1.01 M)
Unlock every fund holding ADVM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ADVM
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ADVM ownership
Insider and institutional ownership, quarter by quarter.

ADVM Short Interest

Shares sold short, counted twice a month.

2.5%
Short % of Float
of tradable shares sold short
435.8K
Shares Sold Short
-46.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
428.2K
Avg Daily Volume
the average used for days to cover
Unlock ADVM short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ADVM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ADVM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ADVM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ADVM ranks across every disease it competes in

Competitive Position is a premium feature
See how ADVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ADVM News

About Adverum Biotechnologies, Inc.

Founded31-07-2014
BIOPHARMAWATCH ELITE PLUS
Trade the next ADVM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime